A new device for diagnosing bone fragility invented by the University Hospitals of Geneva and the University of Geneva has been approved for marketing in the European Economic Area and Switzerland.
BELFAST, UK. (PRWEB) June 07, 2021 ProAxsis Limited (https://proaxsis.com/), the Belfast-based respiratory diagnostics company, is delighted to announce it
NetScientific s ProAxsis Inks Licensing Deal With University Of Geneva
Mon, 22nd Feb 2021 09:30
(Alliance News) - NetScientific PLC on Monday said its portfolio company ProAxsis Ltd has entered a licensing agreement with the University of Geneva and University Hospital of Geneva, for the development of new assays against fractures and other metabolic bone diseases.
ProAxsis is a Belfast-based diagnostics firm, in which life sciences-focused investor NetScientific holds a 95% interest in.
Under the deal, ProAxsis will complete the technical validation of an assay developed by university researchers for a Cathepsin K-dependent periostin cleavage product. The assay is meant to be used as a biomarker for bone fragility related to disorders such osteoporosis.
IN BRIEF: NetScientific s ProAxisis Wins Innovate UK Grant For Project lse.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lse.co.uk Daily Mail and Mail on Sunday newspapers.